Chen Tiffany A, Schachar Ira H, Moshfeghi Darius M
Ophthalmic Surg Lasers Imaging Retina. 2018 Feb 1;49(2):126-131. doi: 10.3928/23258160-20180129-07.
To investigate the outcomes of infants with treatment-warranted retinopathy of prematurity (TW-ROP) who received intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) (IVB) injections as compared to diode laser photocoagulation (DLP).
Data from the Stanford University Network for Diagnosis of Retinopathy of Prematurity database and inpatients at Stanford Children's Hospital were retrospectively reviewed for premature newborns with TW-ROP treated with DLP or 0.625 mg of IVB. Patient characteristics, hospital course, and neurodevelopmental outcomes were compared.
In all, 49 eyes from 25 patients were included; 10 infants (20 eyes) received DLP and 15 infants (29 eyes) received IVB. The IVB infants had significantly fewer diagnoses at the time of discharge and fewer readmissions after initial hospital discharge than the DLP infants (four versus six diagnoses, P = .004; zero versus one readmission, P = .038). At an average of 20 months corrected age, there was no significant difference in neurodevelopmental delay (adjusted odds ratio = 0.87; 95% CI, 0.08-9.46).
Systemic morbidity may be similar among infants treated initially with bevacizumab compared to DLP. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:126-131.].
比较接受玻璃体内注射贝伐单抗（阿瓦斯汀；基因泰克公司，加利福尼亚州南旧金山）（IVB）与接受二极管激光光凝术（DLP）治疗的有治疗指征的早产儿视网膜病变（TW-ROP）婴儿的治疗效果。
回顾性分析斯坦福大学早产儿视网膜病变诊断网络数据库及斯坦福儿童医院住院患者中接受DLP或0.625mg IVB治疗的TW-ROP早产儿的数据。比较患者特征、住院过程及神经发育结局。
共纳入25例患者的49只眼；10例婴儿（20只眼）接受DLP治疗，15例婴儿（29只眼）接受IVB治疗。与接受DLP治疗的婴儿相比，接受IVB治疗的婴儿出院时诊断显著减少，首次出院后再入院次数也更少（诊断次数分别为4次和6次，P = 0.004；再入院次数分别为0次和1次，P = 0.038）。在平均矫正年龄20个月时，神经发育延迟方面无显著差异（校正比值比 = 0.87；95%可信区间，0.08 - 9.46）。
与DLP相比，初始接受贝伐单抗治疗的婴儿全身发病率可能相似。[《眼科手术、激光与影像学视网膜》。2018；49：126 - 131。]
